Under normal circumstances, a drug regulator applies for a review by the regulatory body only after completion of the clinical trials. But in case of a raging epidemic or pandemic, the vaccine maker seeks a "rolling review". In this process, the regulatory body begins analysing the trial data before the completion of the final round of tests.